GLP-3
AED387.55
Advanced metabolic & weight management support
Description
Retatrutide is an investigational once-weekly injectable triple hormone receptor agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors to produce substantial weight loss and improved glycemic control in adults with obesity and/or type 2 diabetes. This was originally developed by Eli Lilly and is also known as Retatrutide.
Additional information
| Specification | 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 50mg, 60mg |
|---|
Related products
Metabolic support & weight management
AED278.55
Select options
This product has multiple variants. The options may be chosen on the product page